CO2021004447A2 - Eritropoyetina humana modificada - Google Patents
Eritropoyetina humana modificadaInfo
- Publication number
- CO2021004447A2 CO2021004447A2 CONC2021/0004447A CO2021004447A CO2021004447A2 CO 2021004447 A2 CO2021004447 A2 CO 2021004447A2 CO 2021004447 A CO2021004447 A CO 2021004447A CO 2021004447 A2 CO2021004447 A2 CO 2021004447A2
- Authority
- CO
- Colombia
- Prior art keywords
- modified human
- human erythropoietin
- erythropoietin
- sites
- neuroplastic
- Prior art date
Links
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 title abstract 2
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 title abstract 2
- 102000044890 human EPO Human genes 0.000 title abstract 2
- 102000003951 Erythropoietin Human genes 0.000 abstract 1
- 108090000394 Erythropoietin Proteins 0.000 abstract 1
- 230000004988 N-glycosylation Effects 0.000 abstract 1
- 230000000913 erythropoietic effect Effects 0.000 abstract 1
- 229940105423 erythropoietin Drugs 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Una eritropoyetina humana modificada con un tiempo de vida media en plasma aumentado, con actividad eritropoyética menor al 0,5 % en relación a una eritropoyetina nativa, que mantiene su capacidad neuroprotectora y neuroplástica, que comprende la mutación de al menos uno de los sitios de unión al receptor homodimérico o heterodimérico mediante la incorporación de sitios consenso de N-glicosilación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP180102793A AR113091A1 (es) | 2018-09-27 | 2018-09-27 | Eritropoyetina humana modificada |
| PCT/IB2019/058179 WO2020065576A1 (en) | 2018-09-27 | 2019-09-26 | Modified human erythropoietin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021004447A2 true CO2021004447A2 (es) | 2021-05-20 |
Family
ID=68425170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0004447A CO2021004447A2 (es) | 2018-09-27 | 2021-04-09 | Eritropoyetina humana modificada |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220220177A1 (es) |
| EP (1) | EP3856223A1 (es) |
| JP (1) | JP2022514728A (es) |
| KR (1) | KR20210070325A (es) |
| CN (1) | CN112770766A (es) |
| AR (1) | AR113091A1 (es) |
| AU (1) | AU2019348911A1 (es) |
| BR (1) | BR112021005968A2 (es) |
| CA (1) | CA3113589A1 (es) |
| CO (1) | CO2021004447A2 (es) |
| IL (1) | IL281843B2 (es) |
| MX (1) | MX2021003614A (es) |
| PE (1) | PE20210827A1 (es) |
| WO (1) | WO2020065576A1 (es) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6709794A (en) * | 1993-04-21 | 1994-11-08 | Brigham And Women's Hospital | Erythropoietin muteins with enhanced activity |
| ZA946122B (en) | 1993-08-17 | 1995-03-20 | Amgen Inc | Erythropoietin analogs |
| US7259146B2 (en) | 2000-05-26 | 2007-08-21 | Ortho-Mcneil Pharmaceutical, Inc. | Neuroprotective peptides |
| US7696163B2 (en) | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| EA010200B1 (ru) * | 2002-07-01 | 2008-06-30 | Дзе Кеннет С. Уоррен Инститьют, Инк. | Рекомбинантные тканезащитные цитокины и кодирующие их нуклеиновые кислоты для защиты, восстановления и усиления чувствительных клеток, тканей и органов |
| EP1527094B1 (en) * | 2002-08-09 | 2008-07-16 | MERCK PATENT GmbH | T-cell epitopes in erythropoietin |
| WO2005025606A1 (en) | 2003-09-09 | 2005-03-24 | Warren Pharmaceuticals, Inc. | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
| US20040091961A1 (en) | 2002-11-08 | 2004-05-13 | Evans Glen A. | Enhanced variants of erythropoietin and methods of use |
| EP1737888A2 (en) | 2004-04-23 | 2007-01-03 | Cambridge Antibody Technology LTD | Erythropoietin protein variants |
| US9988427B2 (en) | 2005-05-13 | 2018-06-05 | Charite Universitaetsmedizen-Berlin | Erythropoietin variants |
| EP1736481A1 (en) | 2005-05-13 | 2006-12-27 | Charite Universitätsmedizin-Berlin | Erythropoietin variants |
| EP1888098A2 (en) | 2005-05-25 | 2008-02-20 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
| US20110003744A1 (en) | 2005-05-25 | 2011-01-06 | Novo Nordisk A/S | Glycopegylated Erythropoietin Formulations |
| US20070072795A1 (en) * | 2005-09-28 | 2007-03-29 | Anton Haselbeck | Treatment of neurodegenerative disorders |
| US20090170759A1 (en) | 2007-07-11 | 2009-07-02 | Virginia Smith-Swintosky | Neuroprotective peptides |
| US20120264686A9 (en) * | 2008-05-29 | 2012-10-18 | Hanall Biopharma Co. Ltd | Modified erythropoietin (epo) polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof |
| WO2013180809A1 (en) | 2012-05-29 | 2013-12-05 | North Carolina Central University | Methods for the production of cytoprotective asialo-erythropoietin in plants and its purification from plant tissues |
-
2018
- 2018-09-27 AR ARP180102793A patent/AR113091A1/es unknown
-
2019
- 2019-09-26 MX MX2021003614A patent/MX2021003614A/es unknown
- 2019-09-26 BR BR112021005968-7A patent/BR112021005968A2/pt unknown
- 2019-09-26 JP JP2021517686A patent/JP2022514728A/ja active Pending
- 2019-09-26 AU AU2019348911A patent/AU2019348911A1/en active Pending
- 2019-09-26 EP EP19797363.9A patent/EP3856223A1/en active Pending
- 2019-09-26 CA CA3113589A patent/CA3113589A1/en active Pending
- 2019-09-26 CN CN201980063851.1A patent/CN112770766A/zh active Pending
- 2019-09-26 WO PCT/IB2019/058179 patent/WO2020065576A1/en unknown
- 2019-09-26 PE PE2021000411A patent/PE20210827A1/es unknown
- 2019-09-26 IL IL281843A patent/IL281843B2/en unknown
- 2019-09-26 KR KR1020217012731A patent/KR20210070325A/ko active Search and Examination
- 2019-09-26 US US17/280,541 patent/US20220220177A1/en active Pending
-
2021
- 2021-04-09 CO CONC2021/0004447A patent/CO2021004447A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3113589A1 (en) | 2020-04-02 |
| IL281843B2 (en) | 2024-04-01 |
| CN112770766A (zh) | 2021-05-07 |
| JP2022514728A (ja) | 2022-02-15 |
| AU2019348911A1 (en) | 2021-04-08 |
| MX2021003614A (es) | 2021-07-21 |
| WO2020065576A1 (en) | 2020-04-02 |
| IL281843B1 (en) | 2023-12-01 |
| AR113091A1 (es) | 2020-01-22 |
| PE20210827A1 (es) | 2021-04-30 |
| EP3856223A1 (en) | 2021-08-04 |
| BR112021005968A2 (pt) | 2021-10-26 |
| IL281843A (en) | 2021-05-31 |
| US20220220177A1 (en) | 2022-07-14 |
| KR20210070325A (ko) | 2021-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002477A1 (es) | Proteínas de fusión interleucina-2/receptor alfa de interleucina-2 y métodos de uso | |
| ES2657060T3 (es) | Fusoquinas que implican citoquinas con afinidades de unión por el receptor fuertemente reducidas | |
| BR112015028457A8 (pt) | Composições cosméticas compreendendo óleo de microalgas | |
| BR112017027869A2 (pt) | degrons dependentes de maltose, promotores responsivos à maltose, construtos de estabilização, e seu uso na produção de compostos não catabólicos | |
| RS54367B1 (en) | MUSIC WITH COMMON LIGHT CHAIN | |
| ECSP21056325A (es) | Compuesto heterocíclico y su uso | |
| EA202092093A1 (ru) | Композиции и способы перепрограммирования tcr с применением слитых белков | |
| BR112017019191A2 (pt) | métodos para reduzir níveis de soro de agentes que contêm fc utilizando antagonistas de fcrn | |
| MX2021005026A (es) | Analogos de cannabinoides y metodos para su preparacion. | |
| EA202091239A1 (ru) | Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение | |
| MX2020012356A (es) | Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes. | |
| MX2022012042A (es) | Composiciones de proteina anti-vegf y metodos para producir la misma. | |
| CO2021004447A2 (es) | Eritropoyetina humana modificada | |
| BR112022005963A2 (pt) | Células com expressão de transgenes sustentada | |
| AR110908A1 (es) | Constructo promotor para la síntesis de proteínas libre de células | |
| BR112022004789A2 (pt) | Proteínas heterodiméricas | |
| BR112018005464A2 (pt) | expressão de proteínas contendo fc | |
| BR112023018832A2 (pt) | Composições de proteínas de fusão quiméricas modificadas e métodos de uso das mesmas | |
| BR112017003074A2 (pt) | Célula isolada, e, métodos de produção de uma proteína recombinante de interesse e de glicosilação de um substrato de proteína de n- glicano. | |
| Mooney | Bronze by Gold by Bloom: Echo, the Invocatory Drive, and the ‘Aurteur'in “Sirens” | |
| SA516370731B1 (ar) | عملية لتحضير جزء وجبة تباع الشمس عالية البروتين | |
| Lucas | Laboratory Excellence and Ethics: An Essential Association | |
| PICARD et al. | Achieving sustainable development in Africa: A governance perspective | |
| Fehn | Nordic Pavilion (1962) and Hedmark Museum (1967–69), Hamar | |
| OGIHARA | Maintenance of Suspension Bridges: Cable Dehumidification |